SuperworthAllarity Therapeutics EPS ALLR
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2024
- −$7997722.61
- Latest quarter, Q2 FY24
- −$2005.38
- Fiscal year 2023
- −$233565.17
Allarity Therapeutics' earnings per share was −$7997722.61 over the twelve months to Jun 30, 2024.
In its latest quarter, Q2 FY24, it was −$2005.38.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2023 | −$233565.17 | n/a |
| FY2022 | −$921474.00 | n/a |
| FY2021 | −$3368400.00 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY24 | −$2005.38 | n/a | −$7997722.61 | |
| Q1 FY24 | −$7968600.06 | n/a | −$8011483.43 | |
| Q4 FY23 | −$198.82 | −100% | −$233565.17 | |
| Q3 FY23 | −$26918.35 | n/a | −$90566.35 | |
| Q2 FY23 | −$15766.20 | n/a | −$624222.00 | |
| Q1 FY23 | −$190681.80 | n/a | −$640795.80 | |
| Q4 FY22 | $142800.00 | n/a | −$921474.00 | |
| Q3 FY22 | −$560574.00 | n/a | −$2811474.00 | |
| Q2 FY22 | −$32340.00 | n/a | −$2393700.00 | |
| Q1 FY22 | −$471360.00 | n/a | −$3268560.00 | |
| Q4 FY21 | −$1747200.00 | n/a | −$3368400.00 | |
| Q3 FY21 | −$142800.00 | n/a | −$1974000.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Allarity Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ALLRAllarity Therapeutics | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Allarity Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.